{"entity":{"id":"oncosting","kind":"company","name":"OncoSTING","aka":["OncoSTING LLC","ONCOSTING LLC"],"tldr":"OncoSTING is developing OS-151, a modified form of the BCG bladder treatment that also releases a strong immune-activating molecule, for bladder cancer. It is in laboratory testing.","summary":"OncoSTING develops recombinant BCG immunotherapies engineered for sustained release of STING agonists. Its lead, OS-151, is a second-generation BCG that produces high levels of a STING agonist while keeping the activity of traditional BCG, aimed at non-muscle invasive bladder cancer and, as an intratumoral therapy, other solid tumours; the company reports it was more effective and better tolerated than traditional BCG in preclinical models. In fiscal year 2026 NCI awarded it USD 1,030,215 under SBIR award 1R44CA310037-01 for STING agonist-expressing BCG in bladder cancer.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://www.oncosting.com/"},{"label":"OncoSTING: technology","url":"https://www.oncosting.com/technology"},{"label":"NIH RePORTER: SBIR award 1R44CA310037-01","url":"https://reporter.nih.gov/project-details/11312959"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":["immunotherapy"],"technologies":["sting-agonist","bcg-and-intravesical-therapy"],"targets":[],"drugs":["os-151"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on oncosting.com and NIH RePORTER on 4 November 2026."],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"hq":"Baltimore, MD","country":"US","companyType":"biotech","website":"https://www.oncosting.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":1030215,"source":"https://reporter.nih.gov/project-details/11312959","note":"NCI SBIR award (R44) 1R44CA310037-01: STING agonist-expressing BCG to enhance bladder cancer therapy"}]},"route":"/companies/oncosting/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"bcg-and-intravesical-therapy","kind":"technology","name":"Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)","route":"/technologies/bcg-and-intravesical-therapy/"},{"id":"sting-agonist","kind":"technology","name":"STING & innate immune agonists","route":"/technologies/sting-agonist/"}],"drug":[{"id":"os-151","kind":"drug","name":"OS-151","route":"/drugs/os-151/"}]}}